Partenaires

Centre National de la recherche scientifique
Logo de l'université de Toulouse Logo de l'Universite Paul Sabatier
Fédération de recherche en biologie de Toulouse



Search

On this website

On the whole CNRS Web


The research at IPBS

The primary objective of the Institute of Pharmacology and Structural Biology, headed by Jean Philippe GIRARD, is the identification and characterization of novel pharmacological targets in the fields of Cancer and Infectious Diseases (Tuberculosis).

The technology portfolio

News All news

27 February 2014

Olivier Neyrolles receives the “Coups d’élan pour la Recherche française” Prize from the Bettencourt Schueller Foundation

On February 26 2014, Dr. Olivier Neyrolles received the Bettencourt (...) Read more

24 January 2014

A group in Toulouse is awarded a prestigious grant to develop a new vaccine against tuberculosis

The University of Toulouse has received funding from Bringham & (...) Read more

30 September 2013

Tuberculosis: how the bacillus feeds upon its host

Tuberculosis still kills nearly 1.5 million individuals every year. A (...) Read more


Seminars

To be noted

SFB congress 2014 "Molecular self-organisation in life processes"

24th Congress of the French Biophysical Society « Molecular self-organisation in life processes” (...)

Press Releases

30 September 2013

Tuberculosis: how the bacillus feeds upon its host

Tuberculosis still kills nearly 1.5 million individuals every year. A (...)

Read more

16 May 2013

Resistance to visceral leishmaniasis : new mechanisms involved

Researchers from CNRS, Université Toulouse III - Paul Sabatier and IRD (...)

Read more

10 May 2013

A new player in migration of immature dendritic cells

When they recognize a pathogen, dendritic cells initiate a maturation (...)

Read more

1 April 2013

Bacterial protein-O-mannosylating enzyme is crucial for virulence of Mycobacterium tuberculosis

A posttranslational protein O-mannosylation process resembling that (...)

Read more

21 December 2012

A new drug target for tuberculosis therapy

One third of the world is infected with the bacterium that causes (...)

Read more